Mette Ødegaard Nielsen

Mette Ødegaard Nielsen

Auto-generated profile, based on publicly available information

Mette Ødegaard Nielsen

Mental Health Center Glostrup, Copenhagen University Hospital

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Biological Psychiatry
Verified
Journal Article
Closed access
MNMette Ødegaard Nielsen
Mette Ødegaard Nielsen
EREgill Rostrup
Egill Rostrup
SWSanne Wulff
Sanne Wulff
NBNikolaj Bak
Nikolaj Bak
HLHenrik Lublin
Henrik Lublin
BGBirte Glenthøj
Birte Glenthøj

1 December 2012 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
MNMette Odegaard Nielsen
Mette Odegaard Nielsen
EREgill Rostrup
Egill Rostrup
SWSanne Wulff
Sanne Wulff
NBNikolaj Bak
Nikolaj Bak
BBBrian Villumsen Broberg
Brian Villumsen Broberg
BGBirte Glenthoj
Birte Glenthoj
Dopamine is an essential neurotransmitter in the brain reward system1,2 and dopaminergic dysfunction has been suggested to be involved in the development of psychotic symptoms.3 A dysregulated hyperdopaminergic state in the striatum might lead to development of psychoses through altered reward processing,4,5 and antipsychotic medication is thought to relieve the psychotic symptoms by normalizing this altered transmission via D2 antagonism.6 As a result, studies of reward processing in schizophrenia are of considerable interest, and studies in unmedicated patients consistently find an attenuated signal in the ventral striatum (VS) during reward anticipation.7,8 This has been suggested to be a result of an increased tonic dopaminergic tone that increases the noise, thereby decreasing the signal to noise ratio. Thus, the event-related blood oxygen level–dependent (BOLD) responses are often smaller, because phasic dopamine responses may not sufficiently differentiate from tonic dopamine levels.9

1 February 2016 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
MNMette Ø. Nielsen
Mette Ø. Nielsen
EREgill Rostrup
Egill Rostrup
SWSanne Wulff
Sanne Wulff
BGBirte Glenthøj
Birte Glenthøj
BEBjørn H. Ebdrup
Bjørn H. Ebdrup
Antipsychotic-associated weight gain predisposes to development of metabolic syndrome and type 2 diabetes mellitus and thereby contributes to a decreased life span by approximately 20 years in patients with schizophrenia.1,2 Quiz Ref ID The weight gain is mediated through complex peripheral and central mechanisms involving various neurotransmitters and neuropeptides.3-5 Histamine H1 receptor blockade may explain in part the pronounced weight gain often associated with clozapine and olanzapine treatment,6-9 whereas serotonin2A receptor blockade may be of importance in quetiapine fumarate–associated weight gain.10 However, antipsychotics with lower histaminergic or serotonergic affinity, such as chlorpromazine hydrochloride and the relatively selective dopamine D2 receptor antagonist amisulpride, are associated with weight gain.11,12 This association suggests that dopamine D2 receptor antagonism may play a critical role in antipsychotic-associated weight gain.13,14

10 July 2020 in Biological Psychiatry
Verified
Journal Article
Open access
KBKirsten Borup Bojesen
Kirsten Borup Bojesen
BBBrian Villumsen Broberg
Brian Villumsen Broberg
BFBirgitte Fagerlund
Birgitte Fagerlund
KJKasper Jessen
Kasper Jessen
MTMarie Bjerregaard Thomas
Marie Bjerregaard Thomas
BGBirte Yding Glenthøj
Birte Yding Glenthøj
Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits. However, the association between cognitive function and levels of glutamatergic metabolites and GABA has not been investigated in a large group of antipsychotic-naïve patients. In total, 56 antipsychotic-naïve patients with schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectroscopy to measure glutamate, glutamate+glutamine (Glx), and GABA levels in dorsal anterior cingulate cortex (ACC) and glutamate and Glx levels in left thalamus. The cognitive domains of attention, working memory, and IQ were assessed. The whole group of antipsychotic-naïve patients had lower levels of GABA in dorsal ACC (p = .03), and the subgroup of patients with a schizophrenia diagnosis had higher glutamate levels in thalamus (p = .01), but Glx levels in dorsal ACC and thalamus did not differ between groups. Glx levels in dorsal ACC were positively associated with working memory (logarithmically transformed: b = −.016 [higher score indicates worse performance], p = .005) and attention (b = .056, p = .035) in both patients and healthy control subjects, although the association with attention did not survive adjustment for multiple comparisons. The findings suggest a positive association between glutamatergic metabolites and cognitive function that do not differ between patients and healthy control subjects. Moreover, our data indicate that decreased GABAergic levels in dorsal ACC are involved in schizophrenia and psychotic disorder, whereas increased glutamate levels in thalamus seem to be implicated in schizophrenia pathophysiology. The findings imply that first-episode patients with cognitive deficits may gain from glutamate-modulating compounds.

17 September 2024 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
RDRiddhita De
Riddhita De
ESEmily C. C. Smith
Emily C. C. Smith
JNJanani Navagnanavel
Janani Navagnanavel
EAEmily Au
Emily Au
KMKateryna Maksyutynska
Kateryna Maksyutynska
Margaret HahnMargaret Hahn
Margaret Hahn
Background: Nonadherence/discontinuation of antipsychotic (AP) medications represents an important clinical issue in patients across psychiatric disorders, including schizophrenia spectrum disorders (SSDs). While antipsychotic‐induced weight gain (AIWG) is a reported contributor to nonadherence, a systematic review of the association between AIWG and medication nonadherence/discontinuation has not been explored previously.Method: A systematic search was conducted in MEDLINE, EMBASE, PsychINFO, CINAHL, and CENTRAL databases, among others, to help identify all studies which explored adherence, study dropouts, AP switching and/or discontinuations attributable to AIWG among individuals with severe mental illness. A meta‐analysis was also completed where applicable.Results: We identified two categories of studies for the meta‐analysis. Category 1 included three studies, which compared measures of AP adherence or discontinuation across BMI classes/degrees of self‐reported weight gain. When compared to normal weight individuals receiving APs or those who did not report AIWG, individuals who were either overweight or obese or reported weight gain in relation to AP use had an increased odds of AP nonadherence (OR 2.37; 95% CI 1.51–3.73; p = 0.0002). Category 2 had 14 studies which compared measures of discontinuation related to weight gain reported as an adverse effect across different APs. Olanzapine was associated with a 3.32 times (95% CI 2.32–4.74; p < 0.00001) increased likelihood of nonadherence or discontinuation when compared to other APs with lower weight gain liabilities. Similarly, APs with moderate weight gain liability (paliperidone, risperidone, and quetiapine) increased the odds of nonadherence or discontinuation by 2.25 (95% CI 1.31–3.87; p = 0.003) when compared to APs considered to have lower weight gain liability (i.e. haloperidol and aripiprazole). The qualitative summary also confirmed these findings.Conclusion: This review and meta‐analysis suggests that AIWG influences medication nonadherence/discontinuation, whereby APs with higher weight gain liability are associated with nonadherence/discontinuation. Additional studies are needed to confirm these findings.

1 June 2018 in Psychoneuroendocrinology
Verified
Journal Article
Open access
DNDorte Nordholm
Dorte Nordholm
EREgill Rostrup
Egill Rostrup
VMValeria Mondelli
Valeria Mondelli
LRLasse Randers
Lasse Randers
MNMette Ø. Nielsen
Mette Ø. Nielsen
BGBirte Glenthøj
Birte Glenthøj
Abnormalities within hypothalamus-pituitary-adrenal (HPA) axis might interact with other neurobiological systems to enhance the risk of psychosis. Most of the neurodevelopmental and HPA axis changes occur in adolescence; this is also the period when prodromal and psychotic symptoms occur for the first time. More knowledge about how various stress components interact can advance understanding of the link between psychosis and the HPA axis. We examined 41 ultra high-risk (UHR) patients and 40 antipsychotic-naïve first-episode schizophrenia (FES) patients and compared them with 47 matched controls. The Perceived Stress Scale and the Recent Life Events Questionnaire were used to assess the stress levels. Day-time saliva samples were taken to measure cortisol. The pituitary gland volume was measured manually on the structural MRI using stereology. Only the UHR patients, had a higher cortisol increase just after awakening (p = 0.009) compared to healthy controls. In UHR patients, we found a negative correlation between cortisol increase after awakening and symptom severity (p = 0.008). Pituitary gland volume and diurnal cortisol were not significantly different among the three groups. There was no correlation between pituitary gland volume, perceived stress/recent life events and any of the cortisol measures or symptoms. Symptom severity during the very early phase of illness (UHR) seems to be associated with altered cortisol increase. Longitudinal studies in UHR patients would be useful to examine how stress levels affect the course of the illness.